Vitamin D has been shown to enhance many types of Chemotherapy
So, be careful about taking vitamin D IF your doctor is unwilling to reduce the amount of chemo to be given.
Chemo dosages were established for the majority of people who have low levels of vitamin D in their blood.
It appears that if you take the normal Chemo dose AND a good level of vitamin D in your blood you will get 2X the impact.
The impact varies with the type of Chemo, suggest that you search PubMed for "name of chemo" "Vitamin D"
CLICK HERE for Chemotherapy and vitamin D - review 2010 PDF they do not seem concerned
Study Shows Benefits of Adding High-Dose Vitamin D to Chemotherapy for Advanced Prostate Cancer: Presented at ASCO
Calcitriol May Safely Double Effectiveness of Taxotere Treatment
ORLANDO, FL — May 21, 2002 — The addition of high-dose calcitriol to weekly treatment with the chemotherapy agent docetaxel (Taxotere®) appears to improve the therapeutic response in men with hormone-refractory prostate cancer without compromising safety, according to results reported at the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO). Calcitriol is the active form of vitamin D.
Data from a phase II clinical trial suggest as much as twice the efficacy with the docetaxel/calcitriol combination than docetaxel alone, as measured by prostate-specific antigen (PSA) response rate. The study showed that 81 percent of patients treated with the combination regimen cut their PSA levels by more than half. Studies of docetaxel without calcitriol have reported a 42 percent PSA response rate overall. PSA is a substance produced within the prostate gland, and a high PSA level may indicate the presence of cancer. In patients with advanced prostate cancer, PSA correlates with the amount of cancer in the body.
"Because there is no standard treatment for hormone-refractory prostate cancer, new therapeutic strategies are clearly needed," said Tomasz Beer, M.D., an oncologist at the Oregon Health & Science University (OHSU) Cancer Institute in Portland, Oregon, and lead investigator of the study. "Docetaxel used alone has shown promise in treating prostate cancer, and our new data strongly indicate that the favorable results can be enhanced with the addition of high-dose vitamin D."
The study included 37 men with hormone-refractory prostate cancer, or disease that was progressive despite standard hormonal therapy, including anti-androgen withdrawal. In addition to PSA response, eight of 15 men with measurable disease responded with significant reductions of their tumors.
Patients in the study received oral calcitriol, 0.5 mcg/kg, (micrograms) on the first day of the treatment cycle, followed by an infusion of docetaxel, 36 mg/m2, on the following day. The treatment was repeated weekly for six weeks of an eight-week cycle until there was evidence of disease progression or unacceptable toxicity, or until the patient requested to be withdrawn from the study.
The results of this phase II study are now the basis for a future phase III study to be conducted at OHSU and other institutions. That randomized study will evaluate the use of weekly docetaxel versus weekly docetaxel plus calcitriol in hormone-refractory prostate cancer.
Prostate cancer is the most common malignancy among men and the second leading cause of cancer death in men in the United States. The American Cancer Society estimates that in 2002, approximately 189,000 men will be diagnosed with the disease, and about 32,200 will die of it. Overall, roughly one in six American men will develop prostate cancer during his lifetime. If detected early, however, treatment can be highly effective.
Oregon Health & Science University is a health and research university focused on improving the well-being of people in Oregon and beyond. OHSU educates health practitioners, bioscientists, high-technology professionals, and environmental scientists and engineers, and it undertakes the indispensable functions of patient care, community service and biomedical research.
To access all OHSU news releases, visit http://www.ohsu.edu/news/
- - - - - - - - - - - - - - -
- - - - - - - - - - - - - - - -
High Prevalence of Vitamin D Deficiency Despite Supplementation in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy
Journal of Clinical Oncology, Vol 27, No 13 (May 1), 2009: pp. 2151-2156
© 2009 American Society of Clinical Oncology.
Katherine D. Crew, Elizabeth Shane, Serge Cremers, Donald J. McMahon, Dinaz Irani, Dawn L. Hershman
From the Department of Medicine, Division of Oncology, Columbia University, College of Physicians and Surgeons; Herbert Irving Comprehensive Cancer Center, Columbia University; and Department of Medicine, Division of Endocrinology, Columbia University, College of Physicians and Surgeons, New York, NY.
Corresponding author: Dawn L. Hershman, MD, MS, Columbia University, 161 Fort Washington Ave, 10-1068, New York, NY 10032; e-mail: dlh23 at columbia.edu.
Purpose Vitamin D deficiency is associated with increased breast cancer risk and decreased breast cancer survival. The purpose of this study was to determine the prevalence of vitamin D deficiency, as measured by serum 25-hydroxyvitamin D (25-OHD), in premenopausal women at initiation of adjuvant chemotherapy for breast cancer and after 1 year of vitamin D supplementation.
Patients and Methods The study included 103 premenopausal women from the northeastern United States with stages I to III breast cancer who received adjuvant chemotherapy and participated in a 1-year zoledronate intervention trial. All patients were prescribed vitamin D3 (cholecalciferol) 400 IU and calcium carbonate 1,000 mg daily. At baseline and at 6 and 12 months, bone mineral density (BMD) measurements were obtained and blood was collected and analyzed in batches for serum 25-OHD. Vitamin D deficiency was defined as serum 25-OHD less than 20 ng/mL, insufficiency as 20 to 29 ng/mL, and sufficiency as 30 ng/mL or greater.
Results At baseline, 74% of women were vitamin D deficient (median, 17 ng/mL). Vitamin D deficiency was slightly less common in white women (66%) compared with black (80%) and Hispanic (84%) women. After vitamin D supplementation for 1 year, less than 15% of white and Hispanic women, and no black women, achieved sufficient 25-OHD levels. Vitamin D levels did not correlate with baseline BMD and were not altered by chemotherapy or bisphosphonate use.
Conclusion Vitamin D deficiency is highly prevalent in women with breast cancer. The current recommended dietary allowance of vitamin D is too low to increase serum 25-OHD greater than 30 ng/mL. Optimal dosing for bone health and, possibly, improved survival has yet to be determined.
Popular Chemotherapy drugs
Wonder how many drugs vitamin D interacts with
Carboplatin (Paraplatin) * used for cancers of the ovary, head and neck, and lung
Cisplatin (Platinol, Platinol-AQ) * used for cancers of the bladder, ovary, and testicles
Cyclophosphamide (Cytoxan, Neosar) * used for lymphoma, breast cancer, and ovarian carcinoma
Docetaxel (Taxotere) * used for breast cancer, lung, and prostate
Doxorubicin (Adriamycin) * used for breast cancer, lymphoma, and multiple myeloma
Erlotinib (Tarceva) * used for non small cell lung cancer
Etoposide (VePesid) * used for cancers of the lung, testicles, leukemia, and lymphoma
Fluorouracil (5-FU) * used for cancers of the colon, breast, stomach, and head and neck
Gemcitabine (Gemzar) * used for cancers of the pancreas, breast, ovary, and lung
imatinib mesylate (Gleevec) * used for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST)
Irinotecan (Camptosar) * used for cancers of the colon and rectum
Methotrexate (Folex, Mexate, Amethopterin) * used for cancers of the breast, lung, blood, bone, and lymph system
Paclitaxel (Taxol, Abraxane) * used with cancers of the breast, ovary, and lung
Sorafinib (Nexavar) * used for advanced kidney cancer
Sunitinib (Sutent) * used for gastrointestinal stromal tumor (GIST) and kidney cancer
Topotecan (Hycamtin) * used for cancers of the ovary and lung
Vincristine (Oncovin, Vincasar PFS) * used for leukemia and lymphoma
Vinblastine (Velban) * used for lymphoma and cancers of the testis and head and neck
- - - - - - - - - - - - - - - - - - - - - - - - - -
Vitamin D in combination cancer treatment.
Cancer. 2010 Jul 15;1:101-7.
Ma Y, Trump DL, Johnson CS.
1. Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
As a steroid hormone that regulates mineral homeostasis and bone metabolism, 1?, 25-dihydroxycholecalciferol (calcitriol) also has broad spectrum anti-tumor activities as supported by numerous epidemiological and experimental studies.
Calcitriol potentiates the anti-tumor activities of multiple chemotherapeutics agents including DNA-damaging agents cisplatin, carboplatin and doxorubicin; antimetabolites 5-fluorouracil, cytarabine, hydroxyurea, cytarabine and gemcitabine; and microtubule-disturbing agents paclitaxel and docetaxel.
Calcitriol elicits anti-tumor effects mainly through the induction of cancer cell apoptosis, cell cycle arrest, differentiation, angiogenesis and the inhibition of cell invasiveness by a number of mechanisms.
Calcitriol enhances the cytotoxic effects of gamma irradiation and certain antioxidants and naturally derived compounds.
Inhibition of calcitriol metabolism by 24-hydroxylase promotes growth inhibition effect of calcitriol.
Calcitriol has been used in a number of clinical trials and it is important to note that sufficient dose and exposure to calcitriol is critical to achieve anti-tumor effect.
Several trials have demonstrated that safe and feasible to administer high doses of calcitriol through intermittent regimen.
Further well designed clinical trials should be conducted to better understand the role of calcitriol in cancer therapy. PMID: 20842231
- - - - - - - - - - - - - - -
Chemotherapy toxicity not associated with vitamin D levels – June 2012
The relationship between vitamin D and chemotherapy-induced toxicity - a pilot study.
Kitchen D, Hughes B, Gill I, O'Brien M, Rumbles S, Ellis P, Harper P, Stebbing J, Rohatgi N.
Br J Cancer. 2012 Jun 26;107(1):158-60. doi: 10.1038/bjc.2012.194. Epub 2012 May 15.
Leaders in Oncology Care (LOC), 95 Harley Street, London W1G 6AF, UK. dkitchen at theloc.com
There are anecdotal data that lower levels of vitamin D may be associated with increased levels of toxicity in individuals receiving chemotherapy; we therefore wished to investigate this further.
From a cohort of over 11 000 individuals, we included those who had vitamin D levels (serum 1,25(OH)(2)D3) measured before and during chemotherapy. They were analysed for side effects correlating Chemotherapy Toxicity Criteria with vitamin D levels, normalising data for general markers of patient health including C-reactive protein and albumin.
A total of 241 (2% of the total cohort) individuals entered the toxicity analysis.
We found no overall difference in toxicity effects experienced by patients depending on whether they were vitamin D depleted or had sufficient levels (P=0.78).
This pilot study suggests routine vitamin D measurement during treatment does not appear to be necessary in the management of chemotherapy-induced toxicity.
Vitamin D: Pharmacokinetics and Safety When Used in Conjunction with the Pharmaceutical Drugs
Used in Cancer Patients: A Systematic Review
Cancers 2013, 5(1), 255-280; doi:10.3390/cancers5010255
Deborah A. Kennedy 1email, Kieran Cooley 1email, Becky Skidmore 1email, Heidi Fritz 1email, Tara Campbell 1email and Dugald Seely 1,2,* email
1 Canadian College of Naturopathic Medicine, 1255 Sheppard Avenue East, Toronto, Ontario, M2K 1E2, Canada 2 Ottawa Integrative Cancer Centre, 29 Bayswater Avenue, Ottawa, Ontario, K1Y 2E5, Canada
- Author to whom correspondence should be addressed.
Received: 21 December 2012; in revised form: 15 February 2013 / Accepted: 1 March 2013 / Published: 11 March 2013
Vitamin D has reported anti-cancer and anti-inflammatory properties modulated through gene transcription and non-genomic signaling cascades. The purpose of this review was to summarize the available research on interactions and pharmacokinetics between vitamin D and the pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high dose calcitriol. The half-life of 25(OH)D3 and/or 1,25(OH)2D3 was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs. No unusual adverse effects in cancer patients; beyond what is expected from high dose 1,25(OH)2D3 supplementation, were revealed through this review. While sufficient evidence is lacking, supplementation with 1,25(OH)2D3 during chemotherapy appears to have a low risk of interaction. Further interactions with vitamin D3 have not been studied.
Keywords: vitamin D; calcitriol; pharmacokinetics; drug interactions; systematic review
PDF is attached at the bottom of this page
See also VitaminDWiki
- All items in category After Cancer Diagnosis 32 items
- Vitamin D appears to both prevent and treat various cancers – Mar 2011
- Is vitamin D the only supplement which consistently helps cancer survivors – Aug 2010
- Cancer survivors helped with lots of Vitamin D – Aug 2010
- Metastatic Cancer is maybe reduced by vitamin D - 5 articles
- Vitamin D3 sensitizes breast cancer to radiation treatment - increasing cancer cell death – May 2010
- Vitamin D reduces lung damage due to radiotherapy – Oct 2011
- Vitamin D and breast cancer radiation
- If vitamin D levels were not changed, toxicity to chemotherapy did not vary with levels – May 2012
- Cancer patients 64% less likely to die if have high level of vitamin D – Dec 2011
- Breast Cancer Chemotherapy initially decreases vitamin D levels – May 2012
- If vitamin D levels were not changed, toxicity to chemotherapy did not vary with levels – May 2012
- Vitamin D levels dropped 3 ng during cancer chemotherapy – May 2012
- Cancer Chemotherapy and vitamin D – Review March 2013
See also web
- PubMed Search for chemotherapy "vitamin d" 10,390 items Nov 2013
- PubMed "cancer treatment" "vitamin d" 91 items Nov 2013
- The beneficial role of vitamin D and its analogs in cancer treatment and prevention 2010
- Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology 2010 PDF attached to this page
- US Clinical Trials for chemotherapy "vitamin d" 27 as of Nov 2013
- US Clinical Trials for chemotherapy INTERVENTION "vitamin d" 22 items Nov 2013, such as
Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients (VITACAL) 100,000 IU at intervals depending on initial deficiency
High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
Study of Vitamin D in Untreated Metastatic Colorectal Cancer (8,000 IU)
- Vitamin D deficiency in oncology patients--an ignored condition: impact on hypocalcemia and quality of life Oct 2012
98% on chemtheraphy has less than 30 ng of vitamin D